Cerus (NASDAQ:CERS – Get Free Report) and Femasys (NASDAQ:FEMY – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Profitability
This table compares Cerus and Femasys’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cerus | -3.06% | -10.19% | -3.14% |
| Femasys | -534.36% | -225.97% | -74.68% |
Valuation and Earnings
This table compares Cerus and Femasys”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cerus | $206.13 million | 2.56 | -$15.63 million | ($0.03) | -87.33 |
| Femasys | $2.29 million | 9.08 | -$18.63 million | ($3.53) | -0.70 |
Cerus has higher revenue and earnings than Femasys. Cerus is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
78.4% of Cerus shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 5.3% of Cerus shares are owned by insiders. Comparatively, 7.7% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Cerus has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, Femasys has a beta of -2.07, indicating that its share price is 307% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Cerus and Femasys, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cerus | 1 | 1 | 3 | 0 | 2.40 |
| Femasys | 1 | 0 | 3 | 0 | 2.50 |
Cerus currently has a consensus target price of $5.25, indicating a potential upside of 100.38%. Femasys has a consensus target price of $50.00, indicating a potential upside of 1,916.13%. Given Femasys’ stronger consensus rating and higher possible upside, analysts plainly believe Femasys is more favorable than Cerus.
Summary
Cerus beats Femasys on 8 of the 13 factors compared between the two stocks.
About Cerus
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.
About Femasys
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.
